Karnav Modi

ORCID: 0000-0003-3351-8829
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mechanical Circulatory Support Devices
  • CAR-T cell therapy research
  • Heart Failure Treatment and Management
  • Cardiac Arrest and Resuscitation
  • Cardiac Structural Anomalies and Repair
  • Multiple Myeloma Research and Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Long-Term Effects of COVID-19
  • Cardiac Valve Diseases and Treatments
  • Hepatitis C virus research
  • Viral Infections and Immunology Research
  • Atrial Fibrillation Management and Outcomes
  • Cardiac Arrhythmias and Treatments
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Pneumonia and Respiratory Infections
  • Cancer-related cognitive impairment studies
  • Erythropoietin and Anemia Treatment
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Sex and Gender in Healthcare
  • Colorectal and Anal Carcinomas
  • Socioeconomic Development in MENA
  • Olfactory and Sensory Function Studies
  • Cannabis and Cannabinoid Research
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Nutrition and Health in Aging

Moffitt Cancer Center
2022-2025

University of Missouri–Kansas City
2023-2025

New York Medical College
2024

B. J. Medical College & Sassoon Hospital
2023-2024

Catholic Medical Center
2023

Mercy Catholic Medical Center
2023

Education Trust
2021

Manipal College of Medical Sciences
2021

Terna Dental College and Hospital
2021

Dhaka Medical College and Hospital
2021

Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how expansion dynamics serum proteomics affect neutrophil recovery phenotypes CD19-directed CAR therapy. Survival favored patients with "intermittent" (e.g., recurrent dips) compared to either "quick" or "aplastic" recovery. While intermittent displayed increased expansion, aplastic exhibited an...

10.1126/sciadv.adg3919 article EN cc-by-nc Science Advances 2023-09-22

Abstract Introduction: CAR-T cell therapy represents a significant advancement in the management of relapsed/refractory hematological malignancies. Adverse events include cytokine release syndrome (CRS), infections, and neurological cardiovascular events. Though real-world data from referral centers regarding uptake different populations incidence various adverse are available, we used National Inpatient Sample (NIS) with weighted analysis to provide contemporary representing national...

10.1158/1538-7445.am2025-3375 article EN Cancer Research 2025-04-21

Abstract Introduction: Myelodysplastic syndromes (MDS) refer to disorders originating from clonal stem cells, marked by ineffective hemopoiesis and cytopenias. Patients with MDS have a higher incidence of cardiovascular mortality, heart failure playing significant role. This has been linked persistent anemia, excess iron accumulation systemic inflammatory state. significantly rates infectious events, pneumonia (PNA) sepsis being the most common infections. The influence systolic (SHF) or...

10.1158/1538-7445.am2025-790 article EN Cancer Research 2025-04-21

Abstract Purpose: Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy associated with an inflammatory state that may exacerbate sarcopenia. The relationship between CAR therapy, sarcopenia, and metabolism poorly understood. Experimental Design: In 83 large B-cell lymphoma patients, the skeletal muscle index (SMI) was measured from clinical images obtained at baseline days 30 90 post-therapy. Serum metabolomics (n=57 patients) performed in first 4...

10.1158/1078-0432.ccr-24-3782 article EN Clinical Cancer Research 2025-04-16
Coming Soon ...